Journal
DRUGS
Volume 81, Issue 3, Pages 397-403Publisher
ADIS INT LTD
DOI: 10.1007/s40265-021-01470-9
Keywords
-
Categories
Ask authors/readers for more resources
Setmelanotide, a melanocortin-4 (MC4) receptor agonist, has been approved in the USA for treating obesity caused by POMC, PCSK1, and LEPR deficiency. It is also being developed for other rare genetic disorders associated with obesity.
Setmelanotide (IMCIVREE (TM), Rhythm Pharmaceuticals) is a melanocortin-4 (MC4) receptor agonist developed for the treatment of obesity arising from proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. The drug has received its first approval in the USA for chronic weight management in patients 6 years and older with obesity caused by POMC, PCSK1 and LEPR deficiency and has been granted PRIority MEdicines (PRIME) designation by the European Medicines Agency for the treatment of obesity and the control of hunger associated with deficiency disorders of the MC4 receptor pathway. Setmelanotide is also being developed in other rare genetic disorders associated with obesity including Bardet-Biedl Syndrome, Alstrom Syndrome, POMC and other MC4R pathway heterozygous deficiency obesities, and POMC epigenetic disorders. This article summarizes the milestones in the development of setmelanotide leading to this first approval for obesity caused by POMC, PCSK1 and LEPR deficiency.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available